Irisquinone exerts anti-osteosarcoma activity by regulating the PI3K/AKT signaling pathway Authors: Ziheng Wu, Xingxing Li, Shunjie Yao, Hao Wang, Yu Wang, Yanchao Ding, Yong Hu Published: 2026 ABSTRACT Irisquinone is an active bioactive constituent isolated from the dried rhizomes of Iris tectorum, a traditional Chinese medicinal herb. Accumulating evidence has confirmed that irisquinone exhibits prominent antitumor activity against a variety of human malignancies. Nevertheless, its biological function and precise molecular mechanisms underlying anti-osteosarcoma effects remain poorly clarified. In the present study, we systematically explored the inhibitory effect of irisquinone on osteosarcoma progression via a combination of in vitro cell experiments and in vivo xenograft model validation. Network pharmacology and molecular docking were applied as preliminary computational strategies to predict potential therapeutic targets and downstream signaling pathways of irisquinone. Bioinformatics analysis indicated that the PI3K/AKT signaling axis is closely implicated in the anti-osteosarcoma action of irisquinone, with AKT1 predicted as a core potential target. Further in vitro functional experiments verified that irisquinone markedly suppressed the proliferation and migration capacity of osteosarcoma cells. Mechanistically, irisquinone restrained the activation of the PI3K/AKT signaling pathway, modulated the expression of apoptosis-related Bcl-2 family proteins (Bax and Bcl-2), and ultimately triggered osteosarcoma cell apoptosis. In addition, the anti-tumor effect and pathway regulatory activity of irisquinone were further validated in vivo. Collectively, our findings demonstrate that irisquinone exerts its anti-osteosarcoma function, at least in part, through suppressing the PI3K/AKT signaling pathway. This work provides reliable experimental support and a theoretical foundation for the preclinical application of irisquinone and the development of novel therapeutic agents against osteosarcoma.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-56227-9. Introduction Osteosarcoma represents the most prevalent primary high-grade malignant bone tumor, predominantly occurring at the epiphyseal regions of long bones in children and adolescents1. Currently, the standard clinical management of osteosarcoma consists of extensive surgical resection, chemotherapy, and radiotherapy2. In recent decades, advances in chemotherapeutic agents and surgical techniques have markedly improved the overall survival of patients with osteosarcoma3. Nevertheless, the long-term survival rate for those with metastatic or recurrent disease remains dismal at only 20–30%4. Furthermore, high-dose chemotherapy frequently induces severe adverse events, including myelosuppression and cardiotoxicity, hepatotoxicity, or nephrotoxicity5. Chemotherapy resistance also represents a major clinical challenge6. Consequently, the development of novel, highly effective, and low-toxicity therapeutic agents for osteosarcoma is urgently required. A growing body of evidence suggests that traditional Chinese medicine (TCM) can be integrated into the clinical management of a considerable number of cancer patients7. Owing to its characteristics including multi-targeted actions and relatively low toxicity, certain TCM agents are widely recognized as complementary therapeutic options for various types of cancer8. Irisquinone is an active compound isolated from the dried seeds of Iris, a traditional Chinese medicinal plant9. As a bio-reductive agent with a quinone structure, it is rapidly metabolized by reductases in the human body, generating related toxic metabolites10. This process takes place more readily in solid tumor cells that are rich in reductases and deficient in oxygen, thus endowing it with selective cytotoxic effects on tumor cells11. In recent years, with increasing research on the pharmacological effects of irisquinone, preclinical and early clinical studies have indicated potential antitumor activities of this compound in multiple cancer types, including nasopharyngeal carcinoma, esophageal cancer, and lung cancer12,13. However, current research on its potential role in the clinical treatment of osteosarcoma—a tumor with a relatively young age of onset and poor drug sensitivity—remains limited, and additional studies are therefore required. Network pharmacology (NP), as an emerging research approach, offers a strategy to understand the specific effects of drugs on complex diseases by clarifying interactions between drugs and targets, as well as their underlying biological mechanisms14. Molecular docking helps us better understand the binding modes and stability of protein-drug complexes15. This study aims to identify the therapeutic targets of irisquinone for osteosarcoma using network pharmacology and molecular docking, and to further explore its mechanism of action against osteosarcoma. Relevant experimental validations have confirmed the antitumor potential of irisquinone in treating osteosarcoma. This research provides a theoretical and experimental basis for promoting the clinical application of irisquinone in drug development and osteosarcoma treatment. The specific workflow of this study is shown in Fig. 1. Fig. 1Network pharmacological analysis, molecular docking and experimental investigation of irisquinone in osteosarcoma. Network pharmacological analysis, molecular docking and experimental investigation of irisquinone in osteosarcoma. Methods The molecular and pharmacological properties data of irisquinone The molecular and pharmacological properties data of irisquinone were obtained from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, (https://old.tcmsp-e.com/tcmsp.php)16 using the search term “irisquinone”. Collection of osteosarcoma- and irisquinone-associated target genes Targets associated with irisquinone and osteosarcoma were retrieved from multiple public databases, including The Comparative Toxicogenomics Database (CTD, https://ctdbase.org/)17, GeneCards (https://www.genecards.org/), PharmMapper (https://lilab-ecust.cn/pharmmapper/submitfile.html)18, SuperPred (https://prediction.charite.de/index.php)19, and SwissTargetPrediction (https://swisstargetprediction.ch/)20. Specifically, osteosarcoma-associated target genes were retrieved from CTD (with the screening criterion of Inference Score (IS) > 20, reflecting the strength of gene-disease association) and GeneCards (with the screening criterion of Relevance Score (RS) > 2, indicating the relevance of genes to osteosarcoma), respectively. Potential targets of irisquinone were predicted from PharmMapper, SuperPred, and SwissTargetPrediction, with the filter thresholds set as Norm Fit > 0.5, Probability > 50%, and probability score > 0.1 (P > 0.1), respectively. To clarify the definition of “osteosarcoma-associated targets” and avoid ambiguity, we define them as genes closely related to the occurrence, development, or progression of osteosarcoma and potential therapeutic targets that may be regulated by irisquinone. The relevance between these genes and osteosarcoma was determined by the screening criteria set for CTD and GeneCards (IS > 20 and RS > 2, respectively), which effectively filter out genes with weak or irrelevant associations with osteosarcoma; meanwhile, we applied strict filtering strategies to ensure that only high-confidence, osteosarcoma-relevant targets were retained, rather than all gene-disease associations retrieved from the databases. All target gene names were standardized using the UniProt database (https://www.uniprot.org/)21 to ensure the consistency and accuracy of subsequent analyses. The molecular structure of irisquinone was downloaded from PubChem (CID: 5318483, https://pubchem.ncbi.nlm.nih.gov/)22. Construction of protein-protein interaction (PPI) networks and analysis of hub targets for irisquinone related to osteosarcoma-associated targets To clarify the overlapping targets between irisquinone and osteosarcoma, cross-targets were screened and visualized using the VENNY 2.1.0 tool (https://bioinfogp.cnb.csic.es/tools/venny/index.html). The protein‑protein interaction (PPI) network of the cross-targets was constructed with the STRING 12.0 database (https://cn.string-db.org/) with species restricted to Homo sapiens, a moderate confidence threshold of 0.4, and no isolated nodes in the network23. Subsequently, the PPI network was visualized and analyzed via Cytoscape 3.8.2 combined with the CytoHubba and MCODE plugins24. For hub target identification using CytoHubba, four algorithms, namely MCC, MNC, Degree, and BottleNeck, were used independently; the top 15 genes from each algorithm were collected, and the intersection of these four gene lists was defined as the final hub targets. MCODE analysis was performed with the following parameters: Degree cutoff = 2, Node score cutoff = 0.2, K‑core = 2, Max depth = 100; modules with a MCODE score ≥ 10 were defined as significant modules. The identified hub targets were then visualized using VENNY 2.1.0. GO and KEGG pathway enrichment analysis The Database for Annotation, Visualization, and Integrated Discovery (DAVID, version 6.8; https://david.ncifcrf.gov/)25 was used to conduct Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis on the identified targets. The species was strictly restricted to Homo sapiens for consistency with previous target screening, and the whole human genome was set as the background gene set. Fisher’s exact test was adopted for statistical analysis, and the Benjamini–Hochberg (BH) correction method was applied for multiple testing to calculate the false discovery rate (FDR). A GO term or KEGG pathway was considered significantly enriched when FDR < 0.05. Expression and prognostic analysis of core targets The publicly available gene expression dataset GSE99671 was retrieved from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/). This dataset includes gene expression profiles of 18 tumoral bone samples and 18 non‑tumoral bone samples. Data normalization was applied, and the expression levels of core target genes were compared between tumoral bone and non‑tumoral bone tissues. Subsequently, RNA‑seq data of osteosarcoma samples and corresponding clinical information were obtained from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database (https://www.cancer.gov/ccg/research/genome-sequencing/target). The primary clinical endpoint was overall survival (OS). Patients were stratified into high‑ and low‑expression groups according to the median expression cutoff of each core target. Time‑dependent receiver operating characteristic (ROC) analysis was conducted using the pROC package in R software to evaluate the prognostic value of core targets, with AUC values and 95% confidence intervals calculated at different time points. Patients who remained alive at the last follow‑up were treated as censored observations. Molecular docking The molecular structures of the key targets were retrieved from the Protein Data Bank (PDB, https://www.rcsb.org/)26, including AKT1 (PDB ID: 7NH5), ESR1 (PDB ID: 2BJ4), HSP90AA1 (PDB ID: 1BYQ), IGF1 (PDB ID: 1B9G), PARP1 (PDB ID: 7KK2) and SRC (PDB ID: 4U5J). Molecular docking was performed using AutoDock Tools 1.5.7 for protein and ligand preparation, including the removal of water molecules, addition of polar hydrogens, and calculation of Gasteiger charges, with AutoDock Vina employed as the molecular docking engine27. Site-directed docking was applied, with the grid box centered on the active pocket of each target protein (grid box size: 20 × 20 × 20 Å, grid spacing: 1.0 Å). The exhaustiveness of the global search algorithm was set to 32, and 10 independent docking runs were performed for each protein-ligand pair in each experiment. All docking experiments were independently repeated in triplicate to ensure stable and consistent binding conformations. The optimal binding conformation with the lowest binding affinity was selected for analysis. Mean binding energies and standard deviation (SD) were calculated for each interaction. All docking results were visualized and analyzed using PyMOL 3.0. Reagents Irisquinone (purity ≥ 98%) was purchased from Chengdu Push Biotechnology Company Limited (Chengdu, China). The phosphoinositide 3‑kinase/protein kinase B (PI3K/AKT) activator, insulin‑like growth factor‑1 (IGF‑1) (Beyotime, Shanghai, China), was used to verify the regulatory effect of irisquinone on the PI3K/AKT pathway in osteosarcoma cells. Irisquinone was dissolved in dimethyl sulfoxide (DMSO), and the final concentration of DMSO in all treatments was ≤ 0.1% to avoid cytotoxicity. IGF‑1 was prepared in the recommended solvent according to the manufacturer’s instructions. An equivalent volume of DMSO was used as the vehicle control in all experiments. Cell culture U2OS, SAOS-2 osteosarcoma cell lines and normal human osteoblast hFOB cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All cells were cultured in DMEM medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) and 1% penicillin-streptomycin. They were maintained at 37 °C in a humidified incubator with a 5% CO2 atmosphere. When the cells reached 80–90% confluence, they were subcultured following standard procedures. CCK-8 assay Adherent osteosarcoma cells were seeded in 96-well plates at a density of 5000 cells per well and treated with different concentrations of irisquinone. After incubation at 37 °C in a 5% CO2 atmosphere for the indicated duration, 10 µL of cell counting kit-8 (CCK-8; Beyotime, Shanghai, China) solution was added to each well. The plate was further incubated at 37 °C for 2 h, and the absorbance at 450 nm was measured using a microplate reader. Wound healing assay Cells were seeded in six-well plates at a density of 1 × 106 cells per well. When the cells reached 90% confluence, they were pretreated with mitomycin C (1 µg/mL, MCE, Monmouth Junction, NJ, USA) for 1 h to inhibit cell proliferation. A 200 µL plastic pipette tip was then used to create uniform scratches on the cell monolayer. After washing three times with PBS (BIOODIN, Guangzhou, Guangdong, China), the cells were incubated with medium containing different concentrations of irisquinone. The scratch healing process was observed and photographed at 0 h and 24 h. Colony formation assay Cells were seeded in 6-well plates at a density of 1000 cells per well. After adherence, cells were treated with irisquinone at the indicated concentrations. The culture medium containing the corresponding concentration of irisquinone was replaced every 3 days to maintain relatively stable drug exposure during the 14-day incubation period. After incubation, the supernatant was discarded. The cells were washed with PBS, fixed in 4% paraformaldehyde (Biosharp, Hefei, Anhui, China) for 30 min, and stained with crystal violet (Beyotime) for 15 min. Subsequently, the cells were rinsed with distilled water, air-dried, photographed under bright-field microscopy, and subjected to further analysis. Flow cytometry for cell apoptosis Cells were seeded in six-well plates at a density of 5 × 105 cells per well and treated with different concentrations of irisquinone for 24 h. After treatment, the cells were harvested, washed twice with PBS, and resuspended in 500 µL of binding buffer. Subsequently, 5 µL of annexin V-FITC and 5 µL of propidium iodide (PI; Bestbio, Shanghai, China) were added to the cell suspension. The mixture was gently mixed and incubated at room temperature in the dark for 15 min. Finally, the cells were analyzed by flow cytometry to evaluate the apoptosis rate. Western blot analysis Osteosarcoma cells were lysed with RIPA buffer (Epizyme, Shanghai, China) supplemented with PMSF and phosphatase inhibitors. The protein concentration was determined using a BCA protein assay kit. Equal amounts of protein (7 µg) were separated by 10% SDS-PAGE and transferred onto PVDF membranes at 400 mA for 55 min. After blocking at room temperature for 1 h, the membranes were incubated overnight at 4 °C with the following primary antibodies: phospho-PI3K (CST, #17366, 1:1000), PI3K (CST, #4257, 1:1000), AKT (HUABIO, #ET1609-51, 1:5000), phospho-AKT (HUABIO, #ET1607-73, 1:5000), BCL2 (Proteintech, #12789-1-AP, 1:2000), BAX (Proteintech, #50599-2-Ig, 1:2000) and γH2AX (CST, #9718, 1:1000). The membranes were then incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibody at a dilution of 1:5000 for 1 h at room temperature. Protein bands were visualized using an ECL detection system and quantified using ImageJ software. β-actin was used as the loading control. For phosphorylated proteins, relative levels were presented as the ratio of phosphorylated protein to total corresponding protein after normalization to β-actin. Animal studies All animal procedures were approved by the Institutional Animal Care and Use Committee of Hefei Comprehensive National Science Center (No. IHM-NF-2023-027) and conducted in accordance with ARRIVE guidelines 2.0. Experimental protocols adhered to the NIH Guide for the Care and Use of Laboratory Animals, with sample sizes determined by statistical power analysis (parameters: α = 0.05, power = 0.8) to ensure ethical animal use and sufficient statistical power for detecting meaningful differences. A sample size of n = 5 per group was justified by this power analysis, which balanced the need for reliable results with the 3R principles (Replacement, Reduction, Refinement) for animal experimentation. Five-week-old female BALB/c nude mice were provided by Skbex Biotechnology Company Limited (Anyang, Henan, China) and housed under specific pathogen-free (SPF) conditions until they reached six weeks of age. A suspension containing 1 × 106 Saos-2 cells in 200 µL cold PBS was subcutaneously injected into the dorsolateral area of each mouse. Approximately 6 days later, when the dorsal tumor volume reached about 50 mm3, the mice were randomly divided into three groups (n = 5 per group) and received intraperitoneal injections every other day for a total of 12 days. Irisquinone was dissolved in a vehicle solution consisting of distilled water containing 0.1% DMSO and 1.8% NaCl. The control group was administered the same volume of the aforementioned vehicle solution as the vehicle control; the low-dose irisquinone treatment group was given 20 mg/kg irisquinone; and the high-dose irisquinone treatment group was given 40 mg/kg irisquinone. During the entire treatment period, mouse body weight was monitored and recorded every three days to assess systemic toxicity induced by the treatment. Tumor length (L) and width (W) were also measured every three days using a vernier caliper, and the tumor volume was calculated using the formula: Tumor volume = 0.5 × L × W2. All measurements were performed by two independent observers to ensure accuracy. At the end of the experiment, all mice were anesthetized with isoflurane prior to euthanasia, following this protocol: Isoflurane (3%–5% concentration) was delivered via a small animal anesthesia machine using oxygen as the carrier gas (flow rate: 0.5–1 L/min). The anesthesia mask was placed over the mouse’s nose and mouth for inhalational anesthesia. Anesthesia induction took 2–3 min, during which the mouse’s condition (respiration, heart rate) was monitored continuously. Anesthesia was deemed effective when the corneal reflex disappeared, muscles relaxed, respiration stabilized, and the mouse showed no response to painful stimuli (pinching the hind paw). Euthanasia was then performed by cervical dislocation. Death was confirmed by the cessation of respiratory movement, dilated pupils with complete loss of light reflex, and no recovery of vital signs after 5 min of observation. After euthanasia, tumors and major organs including heart, liver, spleen, lung, and kidney were harvested immediately, fixed in 4% paraformaldehyde solution for 24 h, embedded in paraffin, sectioned into 5-µm-thick slices, and stained with hematoxylin-eosin (HE) for histopathological analysis. The histopathological sections were observed under a light microscope to evaluate potential off-target toxicity or tissue damage caused by irisquinone treatment, and the relevant results were recorded and described in detail. Tumor tissues were collected, ground in liquid nitrogen, and lysed for protein extraction. The subsequent Western blot experimental procedures were identical to those described above. Statistical analysis GraphPad Prism 8.0.1 was used for all testing. Statistical significance of normally distributed data provided as the mean ± SD was determined using the two-sided Student’s t-test, paired t-test, or one-way ANOVA as appropriate. P < 0.05 was designated as the level of statistical significance. Results Irisquinone inhibits the activity, proliferation, and migration of osteosarcoma cells The chemical structure of irisquinone is shown in Fig. 2A. Given the significant antitumor effects of irisquinone on various tumors, we treated SAOS-2 and U2OS osteosarcoma cells with different concentrations of irisquinone for 24–48 h to investigate its cytotoxic effects on these cells. CCK-8 assays showed that compared with untreated control cells, irisquinone treatment inhibited osteosarcoma cell viability, leading to dose- and time-dependent growth suppression. (Fig. 2B) The IC50 values for SAOS-2 and U2OS cells were 13.61 µM and 11.96 µM at 24 h, and 7.95 µM and 10.24 µM at 48 h, respectively. Subsequently, we further confirmed the inhibitory effect of irisquinone on osteosarcoma cell proliferation using a colony formation assay. The results demonstrated that the colony-forming ability of the cells was significantly reduced as the drug concentration increased. (Fig. 2C) A wound healing assay was used to evaluate the impact of irisquinone on the migratory capacity of osteosarcoma cells. The results showed that the migratory ability of osteosarcoma cells was significantly decreased at higher concentrations of irisquinone. (Fig. 2D) These findings indicate that irisquinone effectively inhibits both the proliferation and migration of osteosarcoma cells. Fig. 2Irisquinone inhibits the activity, proliferation, and migration of osteosarcoma cells. (A) The chemical structure of irisquinone; (B) CCK-8 assay showing irisquinone inhibits osteosarcoma cell (SAOS-2 and U2OS) viability in a time- and dose-dependent manner. Osteosarcoma cells were treated with various concentrations of irisquinone for 24 and 48 h; (C) Irisquinone reduces colony formation of osteosarcoma cells. Colony-formation abilities of SAOS-2 and U2OS osteosarcoma cells were examined after irisquinone treatment for 14 days. (D) Quantitative examination of wound healing experiments showed that the migratory ability of osteosarcoma cells was significantly decreased at higher concentrations of irisquinone. All experiments were independently repeated three times (n = 3), and the data are expressed as mean ± SD. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test to compare differences between groups. Statistical significance was defined as ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared to the control group. Irisquinone inhibits the activity, proliferation, and migration of osteosarcoma cells. (A) The chemical structure of irisquinone; (B) CCK-8 assay showing irisquinone inhibits osteosarcoma cell (SAOS-2 and U2OS) viability in a time- and dose-dependent manner. Osteosarcoma cells were treated with various concentrations of irisquinone for 24 and 48 h; (C) Irisquinone reduces colony formation of osteosarcoma cells. Colony-formation abilities of SAOS-2 and U2OS osteosarcoma cells were examined after irisquinone treatment for 14 days. (D) Quantitative examination of wound healing experiments showed that the migratory ability of osteosarcoma cells was significantly decreased at higher concentrations of irisquinone. All experiments were independently repeated three times (n = 3), and the data are expressed as mean ± SD. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test to compare differences between groups. Statistical significance was defined as ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared to the control group. Irisquinone triggers apoptosis and DNA damage in osteosarcoma cells In the aforementioned experiments, we demonstrated that irisquinone significantly inhibits the proliferation and migration of osteosarcoma cells. To further investigate the apoptotic effects of irisquinone on osteosarcoma cells and its cytotoxic selectivity, we treated SAOS‑2 and U2OS cells as well as normal human osteoblast hFOB cells with different concentrations of irisquinone for 24 h and assessed apoptosis by flow cytometry. The results showed that irisquinone effectively promoted apoptosis in osteosarcoma cells in a concentration‑dependent manner. In contrast, irisquinone exerted only minor pro‑apoptotic effects on normal osteoblast hFOB cells (Fig. 3A). We then used Western blotting to evaluate the expression levels of apoptosis‑related proteins Bcl‑2 and Bax in osteosarcoma cells. As key members of the Bcl‑2 family, Bcl‑2 and Bax are critical regulators of apoptosis that determine mitochondrial membrane permeability and the initiation of apoptosis28. Western blot analysis revealed that irisquinone downregulated the expression of Bcl‑2 and upregulated the expression of Bax in osteosarcoma cells (Fig. 3B). Considering the previously reported chemical properties of irisquinone as a bioreductive compound, we further detected γH2AX expression to evaluate cellular DNA damage. The results showed that irisquinone treatment increased γH2AX accumulation in osteosarcoma cells (Fig. 3C), indicating that irisquinone could cause DNA damage in osteosarcoma cells. These findings demonstrated that irisquinone exerts anti‑tumour activity by inducing cell apoptosis and DNA damage, with relatively low toxicity to normal osteoblasts. Fig. 3Irisquinone promotes apoptosis in osteosarcoma cells with low toxicity to normal osteoblasts. (A) Flow cytometric analysis of apoptosis in SAOS-2, U2OS and normal osteoblast hFOB cells after treatment with irisquinone (0, 8, 16, and 32 µM) for 24 h using Annexin V/PI staining. (B) Western blotting analysis of Bax and Bcl-2 expression levels in SAOS-2 and U2OS cells following 24 h treatment with the indicated concentrations of irisquinone. (C) Western blotting analysis of γH2AX expression levels in SAOS-2 and U2OS cells following 24 h treatment with the indicated concentrations of irisquinone. All experiments were independently repeated three times (n = 3), and the data are expressed as mean ± SD. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test to compare differences between groups. Statistical significance was defined as ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared to the control group. Irisquinone promotes apoptosis in osteosarcoma cells with low toxicity to normal osteoblasts. (A) Flow cytometric analysis of apoptosis in SAOS-2, U2OS and normal osteoblast hFOB cells after treatment with irisquinone (0, 8, 16, and 32 µM) for 24 h using Annexin V/PI staining. (B) Western blotting analysis of Bax and Bcl-2 expression levels in SAOS-2 and U2OS cells following 24 h treatment with the indicated concentrations of irisquinone. (C) Western blotting analysis of γH2AX expression levels in SAOS-2 and U2OS cells following 24 h treatment with the indicated concentrations of irisquinone. All experiments were independently repeated three times (n = 3), and the data are expressed as mean ± SD. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test to compare differences between groups. Statistical significance was defined as ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared to the control group. Preliminary efficacy and safety evaluation of irisquinone against osteosarcoma in a subcutaneous xenograft mouse model. The above experimental evidence indicated that irisquinone could inhibit the growth of osteosarcoma cells in vitro. To further evaluate the antitumor efficacy of irisquinone in vivo, SAOS-2 cells were subcutaneously injected into nude mice. When the tumor volume reached approximately 50 mm3, the nude mice were randomly divided into three groups: the vehicle control group, the low-dose irisquinone group (20 mg/kg), and the high-dose irisquinone group (40 mg/kg). Irisquinone was administered by intraperitoneal injection every other day for a total of 12 days. The results showed that compared with the control group, tumor growth was significantly suppressed in the irisquinone-treated groups in a dose-dependent manner (Fig. 4A–C). Notably, no significant body weight loss was observed in any of the treatment groups during the entire experiment, suggesting that irisquinone was well tolerated (Fig. 4D). In addition, histopathological examination of major organs including the heart, liver, spleen, lung, and kidney showed no obvious tissue damage or pathological abnormalities in the irisquinone-treated groups (Fig. 4E). Fig. 4Preliminary efficacy and safety evaluation of irisquinone in a subcutaneous xenograft mouse model. (A–C) Assessment of tumor growth and weight to evaluate the antitumor effect of different treatments (Vehicle control, irisquinone 20 mg/kg, and irisquinone 40 mg/kg). Tumor volumes were measured every 3 days; representative tumor images, dynamic changes in tumor volume, and statistical analysis of tumor weight are shown. (D) Line graph showing the changes in body weight of mice in different groups during the entire treatment period. (E) Hematoxylin–eosin (HE) staining images of tumor tissues and major organs (heart, liver, spleen, lung, and kidney) from mice in different groups. Data are expressed as mean ± SD, n = 5 mice per group. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control group. Preliminary efficacy and safety evaluation of irisquinone in a subcutaneous xenograft mouse model. (A–C) Assessment of tumor growth and weight to evaluate the antitumor effect of different treatments (Vehicle control, irisquinone 20 mg/kg, and irisquinone 40 mg/kg). Tumor volumes were measured every 3 days; representative tumor images, dynamic changes in tumor volume, and statistical analysis of tumor weight are shown. (D) Line graph showing the changes in body weight of mice in different groups during the entire treatment period. (E) Hematoxylin–eosin (HE) staining images of tumor tissues and major organs (heart, liver, spleen, lung, and kidney) from mice in different groups. Data are expressed as mean ± SD, n = 5 mice per group. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control group. These results suggest that irisquinone effectively inhibits osteosarcoma growth in vivo without obvious systemic toxicity or organ toxicity. Integrated bioinformatics analysis identifies potential targets and pathways of irisquinone against osteosarcoma To explore the potential therapeutic targets and underlying mechanisms of irisquinone against osteosarcoma, integrated bioinformatics analyses were performed. A total of 281 candidate targets of irisquinone were acquired from PharmMapper, Superpred, and SwissTargetPrediction databases, while 346 osteosarcoma-related targets were collected from the CTD and GeneCards databases. Through intersection analysis, 49 common targets were identified as core potential targets of irisquinone for osteosarcoma (Fig. 5A, Table S1–S3). Fig. 5Identification of Irisquinone-related targets, PPI network of irisquinone with the core targets in osteosarcoma setting. (A) Identification of irisquinone-osteosarcoma related targets. (B) Construction of the interactive PPI network using the STRING database, involving the 49 potential drug targets of irisquinone for osteosarcoma. (C) Identification of the top 6 hub targets of irisquinone against osteosarcoma using the CytoHubba plug-in in Cytoscape, applying the degree, MCC, MNC and bottleneck analysis methods. (D) The most significant module was obtained from MCODE. Identification of Irisquinone-related targets, PPI network of irisquinone with the core targets in osteosarcoma setting. (A) Identification of irisquinone-osteosarcoma related targets. (B) Construction of the interactive PPI network using the STRING database, involving the 49 potential drug targets of irisquinone for osteosarcoma. (C) Identification of the top 6 hub targets of irisquinone against osteosarcoma using the CytoHubba plug-in in Cytoscape, applying the degree, MCC, MNC and bottleneck analysis methods. (D) The most significant module was obtained from MCODE. A protein-protein interaction (PPI) network was then constructed based on these 49 targets, which contained 49 nodes and 611 edges, with an average local clustering coefficient of 0.758 and an average node degree of 24.9 (Fig. 5B). The high average node degree and clustering coefficient indicate close functional interactions among these 49 potential targets, suggesting that they may coordinate with each other to regulate biological processes related to osteosarcoma progression, thereby mediating the anti-osteosarcoma effect of irisquinone. To identify core targets with critical regulatory roles, four topological algorithms (MCC, MNC, Degree, and BottleNeck) embedded in the CytoHubba plugin were employed to screen the top 15 genes in each algorithm. The core targets were defined as genes that were consistently ranked among the top 15 by all four algorithms; cross-analysis of the top 15 genes from each algorithm identified six core targets: AKT1, ESR1, HSP90AA1, IGF1, PARP1, and SRC (Fig. 5C). These core targets are well-documented to be closely involved in tumor cell proliferation, apoptosis, invasion, and metastasis, which are key pathological processes of osteosarcoma, confirming their potential as key mediators of irisquinone’s therapeutic effects. MCODE analysis further identified four significant functional modules, among which the highest-scoring module included 27 nodes and 314 edges with a module score of 24.154 (Fig. 5D). The highest-scoring module is primarily enriched in cancer-related signaling pathways and biological processes, including the PI3K/AKT signaling pathway, cell proliferation, and apoptotic regulation—processes that are critical for osteosarcoma development and progression. This suggests that the highest-scoring module may be a key functional unit through which irisquinone regulates osteosarcoma progression via its target genes. To further explore the expression characteristics and potential relevance of these six core targets in osteosarcoma, we analyzed their expression levels using public GEO datasets (GSE99671). Comparison between normal bone tissues and osteosarcoma tissues showed that AKT1, HSP90AA1, and PARP1 exhibited significant differential expression (Fig. 6A), preliminarily suggesting their potential involvement in osteosarcoma progression. We also performed an exploratory analysis to assess the association between core target expression and overall survival of osteosarcoma patients using public data from the TARGET database (Fig. 6B). The results showed that AKT1 and IGF1 had poor initial predictive value for overall survival, with a slight increase in predictive accuracy over time; ESR1, PARP1, and SRC had low predictive value, with their area under the curve (AUC) values below 0.5; HSP90AA1 had certain preliminary predictive value for overall survival within the first year after diagnosis, but its predictive accuracy gradually decreased over time. Collectively, these exploratory results indicate limited prognostic predictive value of the core targets, which only provide preliminary clues for subsequent studies rather than confirming definite clinical or prognostic significance. Fig. 6Expression levels and prognostic value of hub targets in osteosarcoma. (A) The expression levels of hub targets between normal bones and osteosarcoma tissues. (B) Prognostic value of hub targets for overall survival. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared to the control group, respectively. Expression levels and prognostic value of hub targets in osteosarcoma. (A) The expression levels of hub targets between normal bones and osteosarcoma tissues. (B) Prognostic value of hub targets for overall survival. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared to the control group, respectively. GO enrichment analysis showed that the 49 potential targets were mainly involved in the regulation of apoptosis, cell proliferation, and transcriptional activity, which are key processes closely associated with tumor progression. These targets were mainly distributed in the cytosol, nucleus, and cytoplasm, with molecular functions related to protein and enzyme binding (Fig. 7A). Fig. 7GO, KEGG enrichment analysis, and drug-target-pathway network of irisquinone targets against osteosarcoma. (A) Top 10 biological processes, top 10 molecular functions, and top 10 cellular components in GO analysis. (B) Top 10 pathways in KEGG analysis. (C) Drug-target-pathway network illustrating the interactions between irisquinone and its targets in osteosarcoma29–31. GO, KEGG enrichment analysis, and drug-target-pathway network of irisquinone targets against osteosarcoma. (A) Top 10 biological processes, top 10 molecular functions, and top 10 cellular components in GO analysis. (B) Top 10 pathways in KEGG analysis. (C) Drug-target-pathway network illustrating the interactions between irisquinone and its targets in osteosarcoma29–31. KEGG pathway enrichment identified numerous cancer-related pathways, among which the PI3K/AKT signaling pathway was emphasized for further analysis. This pathway was prioritized because it is a well-recognized critical pathway in osteosarcoma proliferation and survival, and our predicted core target AKT1 serves as a central regulator in this pathway (Fig. 7B). A drug-target-pathway network was constructed to visualize the regulatory relationships among irisquinone, its core targets, and the PI3K/AKT pathway (Fig. 7C). These results suggest that irisquinone may exert its anti-osteosarcoma effects at least partially through the regulation of key targets and the PI3K/AKT signaling pathway. Molecular docking validation analysis of core targets We performed molecular docking analysis to predict potential interactions between irisquinone and key targets, aiming to explore their possible binding modes and relative binding affinities. (Fig. 8A–F) The estimated binding energies are presented in Table 1. Notably, AKT1 showed a relatively lower binding energy with irisquinone compared with other targets.It should be noted that molecular docking only provides computational predictions rather than experimental validation of direct target binding. These results support a preliminary hypothesis that irisquinone may potentially affect the PI3K/AKT pathway by interacting with AKT1, which requires further experimental verification. Fig. 8Molecular docking results of irisquinone and hub targets. (A) Irisquinone-AKT1 (B) Irisquinone-ESR1 (C) Irisquinone- HSP90AA1 (D) Irisquinone-IGF1 (E) Irisquinone-PARP1 (F) Irisquinone-SRC. Molecular docking results of irisquinone and hub targets. (A) Irisquinone-AKT1 (B) Irisquinone-ESR1 (C) Irisquinone- HSP90AA1 (D) Irisquinone-IGF1 (E) Irisquinone-PARP1 (F) Irisquinone-SRC. Table 1The binding energy of 6 hub targets and irisquinone, data are presented as mean ± SD of three independent docking runs.ProteinPDB IDLigandBinding energy (kcal/mol)AKT17NH5Irisquinone-5.12 ± 0.27ESR12BJ4Irisquinone-4.14 ± 0.63HSP90AA11BYQIrisquinone-3.72 ± 0.28IGF11B9GIrisquinone-4.35 ± 0.28PARP17KK2Irisquinone-3.91 ± 0.28SRC4U5JIrisquinone-4.53 ± 0.34 Table 1The binding energy of 6 hub targets and irisquinone, data are presented as mean ± SD of three independent docking runs.ProteinPDB IDLigandBinding energy (kcal/mol)AKT17NH5Irisquinone-5.12 ± 0.27ESR12BJ4Irisquinone-4.14 ± 0.63HSP90AA11BYQIrisquinone-3.72 ± 0.28IGF11B9GIrisquinone-4.35 ± 0.28PARP17KK2Irisquinone-3.91 ± 0.28SRC4U5JIrisquinone-4.53 ± 0.34 The binding energy of 6 hub targets and irisquinone, data are presented as mean ± SD of three independent docking runs. Irisquinone suppresses the PI3K/AKT signaling pathway in vitro and in vivo To explore the regulatory effect of irisquinone on the PI3K/AKT signaling pathway, SAOS-2 and U2OS cells were treated with irisquinone for 24 h, and the expression of core pathway proteins was detected by Western blot. The results demonstrated that irisquinone concentration-dependently decreased the phosphorylation levels of PI3K and AKT, while the total protein levels of PI3K and AKT remained unchanged (Fig. 9A). To further clarify whether irisquinone could antagonize exogenous pathway activation, an IGF-1 intervention experiment was performed. In this section, the experimental design included four groups: control, irisquinone single treatment, IGF-1 single stimulation, and combined treatment. IGF-1 alone markedly increased the phosphorylation of PI3K and AKT, confirming its potent activating effect on the PI3K/AKT pathway. Notably, co-treatment with irisquinone significantly attenuated IGF-1-induced pathway activation, indicating that irisquinone can effectively block IGF-1-mediated PI3K/AKT signaling activation in osteosarcoma cells. Quantitative gray value analysis further validated the statistical differences among groups(Fig. 9B). Fig. 9Irisquinone suppresses the PI3K/AKT signaling pathway in vitro and in vivo. (A) Western blotting analysis of p-PI3K, PI3K, p-AKT, and AKT protein expression in SAOS-2 and U2OS cells after treatment with gradient concentrations of irisquinone. (B) Western blotting analysis of p-PI3K, PI3K, p-AKT, and AKT protein expression in SAOS-2 and U2OS cells following co-treatment with irisquinone and IGF-1, and quantitative analysis of relative p-AKT/AKT and p-PI3K/PI3K protein ratios. (C) Western blotting detection of PI3K/AKT pathway-related proteins in xenograft tumor tissues from mice administered with different doses of irisquinone.All experiments were independently repeated three times (n = 3), and the data are expressed as mean ± SD. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test. Statistical significance was defined as ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ns indicates no statistical significance (P > 0.05). Irisquinone suppresses the PI3K/AKT signaling pathway in vitro and in vivo. (A) Western blotting analysis of p-PI3K, PI3K, p-AKT, and AKT protein expression in SAOS-2 and U2OS cells after treatment with gradient concentrations of irisquinone. (B) Western blotting analysis of p-PI3K, PI3K, p-AKT, and AKT protein expression in SAOS-2 and U2OS cells following co-treatment with irisquinone and IGF-1, and quantitative analysis of relative p-AKT/AKT and p-PI3K/PI3K protein ratios. (C) Western blotting detection of PI3K/AKT pathway-related proteins in xenograft tumor tissues from mice administered with different doses of irisquinone.All experiments were independently repeated three times (n = 3), and the data are expressed as mean ± SD. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test. Statistical significance was defined as ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ns indicates no statistical significance (P > 0.05). In addition, the inhibitory effect of irisquinone on the PI3K/AKT pathway was further verified in vivo. Tumor tissues isolated from xenograft mice were subjected to Western blot analysis. Consistent with the in vitro findings, the protein phosphorylation levels of PI3K and AKT were gradually downregulated with increasing irisquinone dosage (Fig. 9C). Collectively, these in vitro and in vivo results demonstrate that irisquinone exerts its anti-osteosarcoma activity through persistent suppression of the PI3K/AKT signaling pathway. Discussion Osteosarcoma is a primary, highly malignant bone tumor predominantly affecting adolescents. Current clinical therapies include extensive surgical resection, chemotherapy and radiotherapy, yet the strong proliferative capacity, rapid progression and early metastatic potential of osteosarcoma cells lead to poor patient prognosis. Moreover, acquired chemoresistance to conventional anticancer drugs severely restricts the clinical management of osteosarcoma32. Thus, the identification of novel and effective therapeutic agents to improve the clinical outcomes of osteosarcoma patients is of urgent clinical necessity. Traditional Chinese medicine (TCM) has emerged as a research hotspot in cancer therapy, attributed to its inherent advantages of multi-targeted action, low toxicity, mild adverse reactions and cost-effectiveness. Exploring antitumor agents from TCM therefore holds great potential and represents a vital research direction7,8. Irisquinone, a bioactive component isolated from TCM, possesses favorable pharmacokinetic properties that comply with the basic criteria for drug development, including an oral bioavailability (OB) ≥ 30%, drug-likeness (DL) ≥ 0.18, molecular weight (MW) < 500 Daltons, hydrogen bond donors (Hdon) < 5 and hydrogen bond acceptors (Hacc) < 10. (Table 2) Accumulating evidence has demonstrated significant antitumor effects of irisquinone in various malignancies, such as inducing tumor cell death, inhibiting proliferation and invasion, and suppressing distant metastasis33,34. Additionally, previous studies have implied that irisquinone is closely associated with the induction of cellular DNA damage. However, its potential inhibitory effect and detailed mechanism in osteosarcoma have not been previously reported. In this study, we for the first time validated the anti-osteosarcoma activity of irisquinone using in vitro and in vivo experimental models, and confirmed that irisquinone exerts dose-dependent effects in reducing osteosarcoma cell viability, inducing apoptosis accompanied by elevated γH2AX expression indicative of DNA damage, and inhibiting cell proliferation and invasion. Table 2The molecular and pharmacological properties data of irisquinone.MWAlogPHdonHaccOB(%)Caco-2BBBDLFASA-TPSARBNHLIrisquinone374.627.210343.871.040.440.400.0043.37163.75 Table 2The molecular and pharmacological properties data of irisquinone.MWAlogPHdonHaccOB(%)Caco-2BBBDLFASA-TPSARBNHLIrisquinone374.627.210343.871.040.440.400.0043.37163.75 The molecular and pharmacological properties data of irisquinone. Network pharmacology, a cutting-edge strategy in systems pharmacology, facilitates a comprehensive understanding of drug actions and their interactions with multiple potential molecular targets35. To elucidate the underlying molecular mechanism of irisquinone in osteosarcoma, we performed network pharmacology analysis, in which 346 osteosarcoma-related targets and 281 irisquinone-related targets were collected. Cross-analysis identified 49 potential targets of irisquinone for osteosarcoma treatment. For these 49 genes, a protein-protein interaction (PPI) network was constructed, followed by KEGG pathway and GO enrichment analyses. KEGG enrichment analysis indicated that the PI3K/AKT signaling pathway is a key pathway mediating the anti-osteosarcoma effects of irisquinone. Six core hub targets (AKT1, ESR1, HSP90AA1, IGF1, PARP1 and SRC) were identified via the CytoHubba plugin. Among these hub targets, AKT1 was selected for subsequent molecular docking analysis due to its well-documented critical role in PI3K/AKT pathway activation and osteosarcoma progression. Analysis of public datasets revealed differential expression of AKT1, HSP90AA1 and PARP1 between osteosarcoma and normal tissues. Molecular docking further yielded a computational prediction that AKT1 may bind to irisquinone, offering a preliminary clue for subsequent exploration of the direct molecular targets of irisquinone in our study. Building on the network pharmacology findings, particularly the KEGG enrichment result that the PI3K/AKT signaling pathway is a key mediator of irisquinone’s anti-osteosarcoma effects, we hypothesized that the anti-osteosarcoma effects of irisquinone may be associated with the PI3K/AKT signaling pathway. Subsequent experimental validation confirmed that irisquinone suppresses PI3K/AKT signaling pathway activation both in vitro and in vivo. Irisquinone dose-dependently downregulates the protein levels of p-PI3K and p-AKT in osteosarcoma cells and tumor tissues, with no obvious changes in the expression of total PI3K and AKT, and it also effectively weakens IGF-1-triggered PI3K/AKT pathway activation. The PI3K/AKT signaling pathway is a central intracellular signaling network activated by various extracellular stimuli and intracellular stressors36, and it plays a pivotal role in regulating fundamental cellular processes, including transcription, translation, proliferation, growth, and survival37. Genome-wide sequencing analyses of osteosarcoma cell lines have demonstrated significant upregulation of AKT expression, indicating widespread activation of the PI3K/AKT pathway in osteosarcoma38–40. This pathway is well-documented to regulate multiple biological functions of osteosarcoma cells: inhibition of the PI3K/AKT pathway induces S and G2/M phase cell cycle arrest, thereby suppressing osteosarcoma cell proliferation41,42; modulation of this pathway alters the expression of E-cadherin and N-cadherin, thus regulating cell viability and the epithelial-mesenchymal transition (EMT) process43; additionally, the PI3K/AKT pathway is involved in mediating chemoresistance of osteosarcoma cells, and targeting this pathway can enhance the antitumor efficacy of conventional chemotherapeutic agents and reverse drug resistance44. These well-documented roles of the PI3K/AKT pathway in osteosarcoma highlight the rationality of our research focus on this pathway, and our findings further reinforce the therapeutic potential of targeting the PI3K/AKT pathway in osteosarcoma, identifying irisquinone as a novel potential small-molecule agent that can effectively suppress the activation of this pathway. This work possesses several strengths in research design. We adopted an integrated research strategy combining preliminary network pharmacology prediction, molecular docking simulation, and comprehensive in vitro and in vivo experimental validation to systematically explore the anti-osteosarcoma activity and molecular mechanism of irisquinone. The present study clarifies the regulatory effect of irisquinone on the PI3K/AKT signaling pathway in osteosarcoma, providing a promising natural compound candidate for basic mechanistic research and therapeutic strategy development of osteosarcoma. Furthermore, we integrated public transcriptomic datasets to profile the expression patterns of core hub genes in osteosarcoma tissues, laying a molecular basis for subsequent in-depth mechanistic exploration. This study also has several unavoidable limitations that need to be acknowledged and addressed in future work. First, molecular docking only provides computational prediction of the interaction between irisquinone and AKT1, lacking direct experimental verification such as cellular thermal shift assay, surface plasmon resonance, or co-immunoprecipitation to confirm their physical binding. Second, although we have verified the inhibitory effect of irisquinone on the PI3K/AKT pathway both in vitro and in vivo, the precise regulatory relationship between irisquinone and upstream/downstream molecules of this pathway remains unclear. Moreover, the potential crosstalk between the PI3K/AKT pathway and other signaling pathways upon irisquinone intervention also requires further exploration. Third, the in vivo mechanism validation was performed in conventional subcutaneous xenograft models, which cannot fully recapitulate the complex tumor microenvironment and clinical heterogeneity of primary osteosarcoma. In addition, we only detected γH2AX as a representative DNA damage marker, and further studies are needed to elaborate the detailed regulatory mechanism of irisquinone-induced DNA damage response. For future research, we will focus on the following directions: first, conduct direct experimental assays such as CETSA and SPR to verify the physical binding between irisquinone and AKT1 and map their precise binding domains; second, apply high-throughput transcriptome sequencing to globally profile the regulatory effects of irisquinone on osteosarcoma cells, and further dissect the crosstalk between the PI3K/AKT pathway and other signaling cascades; third, establish patient-derived xenograft (PDX) osteosarcoma models to further evaluate the anti-tumor efficacy, biosafety and in vivo mechanism of irisquinone in a more clinically relevant setting. Conclusion In summary, this study confirms that irisquinone exerts potent anti-proliferative and pro-apoptotic effects against osteosarcoma both in vitro and in vivo, accompanied by marked inhibition of the PI3K/AKT signaling pathway (Fig. 10). These results highlight the therapeutic potential of irisquinone as a natural bioactive compound for osteosarcoma intervention, and lay a solid foundation for subsequent mechanism exploration and translational research. Fig. 10This study describes a model in which irisquinone inhibits osteosarcoma progression. This study describes a model in which irisquinone inhibits osteosarcoma progression. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2